Edwards Lifesciences Corporation
General ticker "EW" information:
- Sector: Health Care
- Industry: Medical - Devices
- Capitalization: $46.9B (TTM average)
Edwards Lifesciences Corporation follows the US Stock Market performance with the rate: 45.3%.
Estimated limits based on current volatility of 1.6%: low 85.81$, high 88.58$
Factors to consider:
- Company included in S&P500 list
- Total employees count: 15800 (-20.2%) as of 2024
- US accounted for 58.4% of revenue in the fiscal year ended 2023-12-31
- Top business risk factors: Innovate and market, Clinical trial failures, Manufacturing risks, Market competition, Dependence on key physicians
- Price in estimated range
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [72.41$, 104.70$]
- 2026-12-31 to 2027-12-31 estimated range: [75.21$, 108.62$]
Financial Metrics affecting the EW estimates:
- Negative: with PPE of 33.6 at the end of fiscal year the price was high
- Positive: Operating profit margin, % of 20.61 > 18.39
- Positive: Return on assets ratio (scaled to [-100,100]) of 7.16 > 6.06
- Positive: -0.02 < Operating cash flow per share per price, % of 3.17
- Positive: Inventory ratio change, % of -0.77 <= -0.75
- Positive: -4.41 < Investing cash flow per share per price, % of -1.42
Short-term EW quotes
Long-term EW plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $5,010.00MM | $5,439.80MM | $6,134.80MM |
| Operating Expenses | $3,701.10MM | $4,061.10MM | $4,870.60MM |
| Operating Income | $1,308.90MM | $1,378.70MM | $1,264.20MM |
| Non-Operating Income | $63.50MM | $169.40MM | $8.70MM |
| Interest Expense | $17.60MM | $19.80MM | $20.40MM |
| R&D Expense | $962.90MM | $1,053.00MM | $1,079.20MM |
| Income(Loss) | $1,372.40MM | $1,548.10MM | $1,272.90MM |
| Taxes | $152.40MM | $152.10MM | $216.90MM |
| Other Income(Loss) | $179.40MM | $2,773.70MM | $13.40MM |
| Net Income(Loss)* | $1,402.40MM | $4,174.60MM | $1,073.50MM |
| Stockholders Equity | $6,650.00MM | $9,998.40MM | $10,337.60MM |
| Inventory | $903.50MM | $1,086.70MM | $1,126.20MM |
| Assets | $9,363.20MM | $13,055.30MM | $13,697.20MM |
| Operating Cash Flow | $895.80MM | $542.30MM | $1,595.20MM |
| Capital expenditure | $266.30MM | $252.40MM | $260.20MM |
| Investing Cash Flow | $173.80MM | $2,312.90MM | $-712.90MM |
| Financing Cash Flow | $-711.00MM | $-983.00MM | $-956.80MM |
| Earnings Per Share** | $2.31 | $6.98 | $1.84 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.